VRT106 / Guangzhou Virotech - LARVOL DELTA

Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. (PubMed, Clin Cancer Res) - P1 | "The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC."

Journal • Hematological Disorders • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Influenza • Oncology • Respiratory Diseases • Solid Tumor

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.

New P1/2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

Oncolytic virus M1-c6v1 combined with camrelizumab and apatinib in patients with advanced hepatocellular carcinoma: A phase 2 open-label trial evaluating safety, and efficacy (APASL 2025) - P1 | "This study demonstrates that the combination of oncolytic virus M1-c6v1 with apatinib and camrelizumab has promising efficacy and manageable safety in patients with advanced HCC. The regimen may represent a novel therapeutic option for these patients. The trial is ongoing, and further results will be reported in due course."

Clinical • Metastases • Oncolytic virus • P2 data • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Influenza • Oncology • Respiratory Diseases • Solid Tumor

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. | Trial primary completion date: Aug 2025 ➔ Jun 2026

Trial primary completion date • Oncology • Solid Tumor

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: Xiangya Hospital of Central South University

New P1/2 trial • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.

New P1 trial • Oncology • Solid Tumor

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination with Chemotherapy for Resectable Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Guangdong Provincial People's Hospital

New P1/2 trial • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Virotech: Oncolytic virus M1 intravenous injection was implicitly approved by the State Food and Drug Administration for clinical trials [Google translation] (bydrug.pharmcube.com) - "On December 2, 2024, the oncolytic virus M1 (VRT106) developed by Guangzhou Virotech Pharmaceutical Technology Co., Ltd...received the implicit approval of clinical trials from the National Medical Products Administration (NMPA) to carry out intravenous phase I clinical trials in patients with advanced solid tumors in China....The approved Phase I clinical trial will focus on evaluating the safety, tolerability, and pharmacokinetic profile of intravenous VRT106 and exploring its potential efficacy in patients with advanced or metastatic solid tumors."

New P1 trial • Oncology • Solid Tumor

Construction of oncolytic virus commercial production line [Google translation] (Sohu.com) - "The background of this project is that VRT106 for injection has entered the Phase I clinical stage and will enter Phase II clinical research in 2025. Faced with the demand for funds for clinical trials and the demand for commercial production sites for market sales, the company intends to settle down and build a commercial-scale oncolytic virus production line locally, while conducting multiple Phase II and Phase III clinical studies of VRT106 for injection for tumor indications....This project plans to conduct 2-3 Phase I/II clinical trials and at least 1 Phase III clinical trial of VRT106, and it is expected to apply for conditional drug marketing in China or Japan in 2028."

China filing • Commercial • Japan filing • New P2 trial • Trial status • Oncology • Solid Tumor

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncolytic virus • Oncology • Solid Tumor

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. | Trial completion date: May 2026 ➔ Dec 2026 | Initiation date: Dec 2023 ➔ May 2024 | Trial primary completion date: Jan 2025 ➔ Aug 2025

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor